September is PCOS/PMOS Awareness Month which usually means a lot of teal ribbons and not a lot of actual clinical clarity. So let’s fix that.

If you’ve been living with a PCOS diagnosis, you already know the drill: irregular cycles, an ultrasound report full of language nobody explained, and a Pinterest board’s worth of conflicting advice about seed cycling and inositol.

Here’s the update most awareness-month content won’t tell you: as of May 2026, an international consensus in The Lancet renamed PCOS to PMOS — polyendocrine metabolic ovarian syndrome. Not because the condition changed. Because the name was always kind of a lie.

“Polycystic ovary syndrome” made it sound like the problem was cysts on your ovaries. It’s not. There are no cysts. What you’re actually looking at is a whole-body endocrine and metabolic condition that happens to show up on an ovarian ultrasound — which is exactly why “polyendocrine metabolic ovarian” is a mouthful, but an honest one.

The diagnostic criteria haven’t changed. The 2023 framework still applies. What changed is the framing — and honestly, the framing matters, because it’s the difference between “I have ovary cysts” and “I have a systemic condition that touches my glucose, my lipids, my sleep, my mood, and yes, my ovaries too.”

Let’s talk about what a real PMOS workup should actually include — because most people never get one.

The diagnosis is a diagnosis of exclusion. Act like it.

To meet adult criteria, you need two of three: hyperandrogenism (clinical or on labs), ovulatory dysfunction, and either polycystic morphology on ultrasound or an elevated AMH. If you already have irregular cycles and signs of high androgens, you don’t even need the ultrasound.

But here’s the part that gets skipped constantly: PMOS is a diagnosis you arrive at only after ruling other things out. Thyroid disease. Hyperprolactinemia. Nonclassic congenital adrenal hyperplasia. Hypothalamic dysfunction. Ovarian insufficiency. If your workup was “your ultrasound showed follicles, so it’s PCOS” — that’s not a diagnosis, that’s a guess.

Your hormone panel is not the whole story

A testosterone and an AMH do not constitute a workup. A real evaluation is answering four separate questions:

• Do you actually meet criteria?

• Is something else mimicking this?

• What metabolic and psychological risk needs addressing right now?

• Is there another fertility factor hiding behind the PMOS label?

That last one trips people up constantly. High AMH or a busy-looking ovary on ultrasound does not automatically mean you need IVF — and it definitely doesn’t mean anovulation is your only obstacle to pregnancy.

The test nobody orders (and the one everybody does that they shouldn’t)

Here’s a genuinely underrated detail from the current guidance: routine fasting insulin and HOMA-IR are not recommended. I know — every wellness influencer on your feed is obsessed with insulin resistance panels. But the international guideline is clear that these assays aren’t standardized enough to guide decisions. What isrecommended, and what gets skipped constantly, is the 75-gram oral glucose tolerance test. Not fasting glucose. Not HbA1c alone. The full OGTT — because it catches impaired glucose tolerance that a normal fasting number will happily hide.

Pair that with a fasting lipid panel, blood pressure, a sleep apnea screen (yes, even if you’re not “textbook” high weight — PMOS carries independent risk), and a depression/anxiety and eating-disorder screen. Not optional add-ons. Part of the core evaluation.

The part that actually surprises people: IVF is usually not first-line

If anovulation from PMOS is your only fertility obstacle, IVF is generally third-line. Not because it doesn’t work — because it skips steps that work first, with less cost, less physical burden, and less risk.

The evidence-based sequence looks like this:

1. Foundation — lifestyle and metabolic optimization (not as a delay tactic, as actual preparation)

2. First-line — letrozole. In head-to-head trials, letrozole beat clomiphene on both ovulation (61.7% vs. 48.3%) and cumulative live birth (27.5% vs. 19.1%)

3. Second-line — carefully monitored low-dose gonadotropins, or selected laparoscopic ovarian surgery

4. Third-line — IVF, with or without ICSI

IVF moves up the list fast if there’s another factor in play: blocked tubes, severe male-factor infertility, a genetic indication, or an age/reserve situation where time is the limiting resource. But “your AMH is high” is not, by itself, a reason to skip straight to retrieval.

Preconception is not a formality

PMOS pregnancies carry higher average odds of miscarriage, gestational diabetes, preeclampsia, and preterm birth. That’s not a scare tactic — it’s the reason preconception OGTT, blood pressure optimization, and medication review (metformin does not prevent gestational diabetes or preeclampsia, by the way — that’s a common misconception) matter before you’re actively trying, not after a positive test.

The bottom line

A single hormone panel and a normal fasting glucose do not complete a PMOS workup. This is a whole-body condition, and your care should reflect that — diagnosis confirmed, mimics excluded, metabolic and psychological risk mapped, endometrium protected, both partners evaluated when pregnancy is the goal, and treatment matched to your actual priorities, not a generic protocol.

Awareness months come and go, but if there’s one thing worth taking from this September: PMOS is a lifelong, whole-body condition, and it deserves a whole-body workup — not just a scroll-stopping ultrasound photo and a hashtag.

Already did a retrieval and staring at a report full of numbers nobody explained?

That’s a different problem than the one above — and it’s the one I built the Embryology Consult to solve.

This is a focused, one-on-one review of your actual IVF cycle data with me — a clinical embryologist who has read thousands of reports just like yours. No jargon dump, no rush job. Just a clear, honest read of what your data shows and what it means for what’s next.

What’s included:

• Stimulation Protocol Review — your meds, dosing, follicle response, trigger timing, and retrieval outcomes, with full clinical context

• Embryology Report Review — fertilization rates, maturity, day-3 and day-5 development, blastocyst grades, arrest patterns, and PGT results, explained the way an embryologist actually explains them

• Strategic Fertility Roadmap Report — a written summary of what your data shows, what can be optimized next cycle, and a curated list of questions to bring to your REI or lab team

This is right for you if:

• You have one or more completed IVF cycles and want your data fully explained

• Your embryos arrested early or didn’t reach blast, and you want to understand why

• You got your results and want context — and sharp questions — before your next appointment

• You’re prepping for another cycle and want an independent second opinion first

Note: this consult covers your stimulation and embryology data only — no bloodwork review or full systems workup. If you want the deeper dive, the OVAHaul Analysis or Full OVAHaul System is your next step.

👉 Schedule your Embryology Consult

Your data has answers. You just need someone who speaks the language.



With you every step,

Lindsay Chu
Founder of OVAHaul

An extended follow-up of a multi-center randomized controlled trial (824 women, all without severe male factor, all single blastocyst transfers) found that conventional IVF outperformed ICSI on the outcomes that matter most. In the per-protocol analysis, cumulative live birth rate was 50.3% with conventional IVF versus 43.0% with ICSI. Even more striking: the chance of getting two children from a single retrieval cycle was 11.6% with IVF versus 7.0% with ICSI. If you are building a family, not just chasing one positive test, fertilization method matters.

A separate analysis of more than 120,000 embryos found ICSI-derived embryos showed abnormal first cell divisions at 52% versus 41% for conventional IVF. The likely reason: ICSI bypasses the natural selection process where sperm must compete, capacitate, and penetrate the egg on their own merits.

The takeaway is not that ICSI is bad - it remains essential for severe male factor, prior fertilization failure, and surgically retrieved sperm. The takeaway is one question every patient should ask: “Is ICSI specifically indicated for my case, or is it just your default?”

If you also want to improve your fertilization and cumulative live birth outcomes, join the waitlist for the OVAHaul Community - our Fertility Investigation and Optimization Membership. Founding Cohort spots are limited, with exclusive pricing, early access, and benefits that will not be available once we open to the public in Fall 2026. This is for you.

With you every step of the way,

Lindsay Chu
Founder OVAHaul
Clinical Embryologist

SOURCES

Berntsen S, et al. No advantage of ICSI over IVF in the absence of severe male factor: cumulative deliveries from a multicentre randomized controlled trial. Human Reproduction, Vol 41, Suppl 1 (ESHRE Abstract L26/P-276). DOI: 10.1093/humrep/deag083.612

Abnormal early cleavage in ICSI vs conventional IVF embryos (>120,000 embryos, time-lapse analysis). Reproductive BioMedicine Online, RBMO Insights Issue 51.

https://www.linkedin.com/pulse/rbmo-insights-issue-51-august-2026-reproductive-biomedicine-online-7z6zf

If you have ever transferred a beautiful, genetically normal embryo and gotten a negative test anyway, you know the specific ache of that question: it was a good embryo, so what happened?

For years the honest answer was a shrug. This week, science handed us a genuinely new piece of the puzzle.

The study that reframes reproductive aging

We talk about fertility aging like it lives entirely in the ovaries. Fewer eggs, more chromosomal errors, done. But a study published August 6 in Cell Host & Microbe, one of the top microbiome journals in the world, just showed that the uterine lining ages too, and the bacteria living in it are active players in that process.

Researchers at Peking University Third Hospital studied 149 women going through infertility treatment and found that a protective bacterium called Lactobacillus gasseri steadily declines in the endometrium with age. Meanwhile a less helpful species, L. iners, moves in and takes its place. Think of it as a neighborhood slowly losing its best tenants.

Then they followed these women for a year. The ones who got pregnant after embryo transfer had more Lactobacillus in their uterine lining than the ones who did not.

Here is where it gets wild

The team did not stop at correlation. They traced the mechanism all the way down.

L. gasseri produces a substance called an exopolysaccharide, or EPS. When they tested it on human endometrial cells, the EPS protected those cells from senescence, the biological state where cells stop working properly but stick around causing inflammation. When they engineered a version of the bacterium that could not make EPS, the protection vanished. Add the EPS back, protection restored.

In aged mice, treating with L. gasseri reduced cellular aging markers in the uterus, reduced fibrosis (scarring), and improved embryo implantation rates. The pathway involved is called Hippo-YAP, and it controls the genes your endometrium needs to switch on to accept an embryo. Aging jams that switch. This bacterium’s EPS appears to un-jam it.

In plain terms: an aging uterus loses a bacterium whose byproduct keeps the lining young and receptive, and restoring that byproduct reversed much of the damage. In mice. So far.

What this means for you (and what it does not)

If you are over 35 and have experienced repeated implantation failure with good embryos, this study says something important: your uterine environment is its own system, aging on its own timeline, and standard testing barely looks at it. An ERA tells you about timing. An ultrasound tells you about thickness. Neither tells you who is living in your lining.

Endometrial microbiome testing (EMMA) already exists and can identify whether your lining has shifted away from a protective Lactobacillus profile. That is actionable information today.

What is NOT actionable today: buying L. gasseri capsules off Amazon. The researchers explicitly caution against this. Oral supplements have never been validated for the endometrium, the effective formulation in this study was delivered locally, and the human trials have not happened yet. Please do not let a supplement company turn this beautiful study into a $60 bottle of false hope.

The bigger picture

This is exactly the pattern I keep telling you about. The endometrium is not a passive recipient of embryo quality. It accumulates oxidative stress, inflammation, and senescent cells just like the ovaries do, driven by many of the same mechanisms. The microbiome is one more layer in that system, capable of either amplifying the aging or slowing it down.

Which means implantation failure is rarely one thing. It is a systems question. Immune, inflammatory, metabolic, microbial, all of it talking to each other while you are told to “just try again.”

If you have optimized everything on the embryo side and your transfers still are not sticking, the uterine environment is the conversation nobody has had with you yet. It is one I have with patients every week.

Schedule your consult and start your OVAHaul journey →

We will look at your full picture, including the systems your clinic is not testing, and build a plan that treats your body like the interconnected thing it actually is.

Until next week, stay curious about the parts of the story nobody is talking to you about.

With you every step,

Lindsay Chu
Embryologist
Founder of OVAHaul

Lindsay Chu, MS, is the founder of OVAHaul, a fertility systems investigation service. This newsletter is educational and not medical advice.

If you’ve been through IVF, you’ve likely heard some version of this: blastocysts are better, day-5 transfer is the goal, extending culture is the right call. And there’s truth to parts of it. But the full picture is more nuanced — and the January 2026 update to the Cochrane systematic review on this question makes that clear.

Here’s what the updated review actually says:

Blastocyst transfer does improve live birth rates per fresh transfer cycle. That part holds up. But when you look at cumulative live birth rates — meaning all the frozen embryo transfers from the same egg retrieval factored in — the advantage is less consistent across all patients and all lab settings.

The review flags something important: extended culture to blastocyst may function partly as a selection tool. Embryos that survive to day 5 in the lab are the ones that survived. That’s not the same as saying they were biologically superior — it may mean that some embryos that wouldn’t have made it to day 5 in the lab would have continued developing in the uterus, where conditions are different.

For patients with a limited number of embryos, this is a meaningful distinction. The universal push to blastocyst culture may not serve everyone equally.

If you have a small cohort, multiple failed blastocyst transfers, or you’ve been told there’s “nothing to transfer” after extended culture — this is relevant to your case.

Understanding the data behind transfer decisions is exactly the kind of review we do in an OVAHaul Embryology Consult. We look at your IVF history, your embryo outcomes, and what the evidence actually supports for your specific situation.

👉 Schedule a consult with Lindsay — let’s look at your embryo data together.

With you every step,

Lindsay Chu

Founder, OVAHaul | Clinical Embryologist, MS Reproductive Clinical Science @lindsayatovahaul | ovahaul.com

When you go through IVF with a GnRH antagonist protocol (the most common type used today), the stimulation process suppresses your body’s natural hormonal signals. Progesterone supplementation after retrieval is standard. But estrogen? Often overlooked. The luteal phase environment created by controlled ovarian stimulation tends to be progesterone-dominant but estrogen-deficient — and that imbalance matters for implantation.

A randomized controlled trial published in May 2026 in Human Reproduction Open directly tested this. They evaluated vaginal estrogen supplementation added to standard luteal phase support in women undergoing IVF with antagonist protocols. The results are drawing attention from clinicians who have long suspected that estrogen support in this window was under-addressed.

This doesn’t mean everyone needs estrogen supplementation. It means there’s now RCT-level data to have an informed conversation with your doctor — which, until recently, didn’t exist.

If you’ve had failed transfers on antagonist protocols and your luteal support has only included progesterone, this is worth looking at.

The hormonal system domain is one of the 10 systems we investigate at OVAHaul. Luteal phase adequacy — including both progesterone and estrogen — is part of how we interpret your data.

If you want to walk through your protocol history and understand whether your luteal support has been optimized, I’d love to look at it with you.

👉 Schedule a consult with Lindsay — we’ll go through your cycle data together.

With you every step,

Lindsay Chu
Founder, OVAHaul | Clinical Embryologist, MS Reproductive Clinical Science @lindsayatovahaul | ovahaul.com

Have you experienced two losses? Three losses? Maybe more? And often, at the end of the workup, the same answer: everything looks normal. We don’t have a reason.

That answer is not nothing — it carries real weight. And the fact that medicine hasn’t always had a clear framework for what to look at next has left a lot of patients without a path forward.

The American Society for Reproductive Medicine just published its most significant update to recurrent pregnancy loss guidelines in years. Here’s what changed, in plain language.

Uterine structure should now be evaluated in everyone with unexplained RPL.

Not selectively. Not only if something looks obviously wrong on a standard ultrasound. The updated guidance makes this a standard recommendation. Structural issues — including a uterine septum or polyp — may be treatable when found, and the guidance now explicitly supports offering those interventions.

Antiphospholipid syndrome (APS) remains the most clearly treatable immune cause of loss.

APS is an autoimmune clotting condition. It’s diagnosable. It’s manageable. And it requires specific testing — done twice, 12 weeks apart — to rule in or rule out. If you’ve had basic immune panels but not a full APS workup, this is worth revisiting.

For PMOS patients with insulin resistance, metformin is now recommended — even without an abnormal glucose tolerance test.

This is a meaningful shift. Insulin resistance is a driver of early pregnancy loss in PMOS, and the bar for addressing it has been lowered. You no longer need a formal GTT failure to justify treatment.

PGT-A benefit in RPL now has clear age-stratified data.

The adjusted odds ratio for live birth with PGT-A versus without is 1.31 under age 35 — modest. It rises to 3.80 over age 42 — substantial. Age matters significantly in how much genetic testing of embryos can change outcomes.

Vaginal progesterone is now a legitimate option — on a shared decision-making basis.

For patients with vaginal bleeding in early pregnancy or recurrent unexplained loss, vaginal progesterone may be offered. The framing is shared decision-making, which is a more honest acknowledgment that the risk-benefit calculation is personal.

HbA1C is now part of the recommended workup if metabolic risk factors are present.

Blood sugar control matters for early pregnancy. It belongs in the investigation when there’s any reason to suspect it.

If you’ve had losses and been left without a clear explanation, these updates matter because they expand what “a thorough workup” is supposed to include. You’re not out of options just because the standard panel came back normal.

This new guideline isn’t the end all be all to investigate either. It is just a START.

The OVAHaul consults are designed exactly for this — looking at your fertility data the way it deserves to be looked at. Whether you want your IVF embryology report fully explained, a complete investigation into what your bloodwork and cycle data have been missing, or the most comprehensive root cause analysis available for both partners, there is a starting point for where you are right now.

Each consult includes dedicated one-on-one time with Lindsay, a clinical embryologist, and a personalized roadmap built entirely around your results. Click below to learn more about all three and find your starting point.

👉 Schedule a consult with Lindsay

With you every step of the way,

Lindsay Chu
Founder, OVAHaul | Clinical Embryologist, MS Reproductive Clinical Science @lindsayatovahaul | www.ovahaul.com

There is a blood test that takes two standard lab values, calculates a single number, and has been shown in published research to be associated with a miscarriage odds ratio of 3.56 in non-PCOS women when elevated.

It is called HOMA-IR. And it is almost never ordered in a standard fertility workup.

HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. It requires a fasting glucose and a fasting insulin drawn at the same time. Those two numbers generate a calculation that tells you how resistant your cells are to insulin signaling right now, before you have crossed any threshold that would generate a diabetes diagnosis.

This is the critical distinction. Standard glucose testing is designed to identify diabetes. It is not designed to identify the sub-clinical insulin resistance that disrupts follicular biology. A patient can have completely normal glucose and A1C values while carrying a HOMA-IR that is quietly affecting every ovarian cycle she has.

Here is what insulin resistance at the pre-clinical level does inside the follicle.

Insulin excess in the ovarian environment increases androgen production inside the theca cells of the follicle, independently of LH. It suppresses hepatic SHBG synthesis, which means more free androgens circulating in your system. It impairs oocyte cytoplasmic maturation in ways that are invisible to stimulation monitoring. And it alters the metabolic signaling environment that early embryo development depends on.

Yang 2022 documented the downstream consequence clearly: a HOMA-IR at or above 2.71 in non-PCOS women was associated with a miscarriage odds ratio of 3.56. That is not a subtle signal. That is a clinically significant finding attached to a test that costs almost nothing to run.

The target before an IVF cycle is HOMA-IR below 1.0.

Getting there is absolutely achievable. The evidence-based intervention is Mediterranean dietary pattern as the foundation, 150 minutes per week of combined aerobic and resistance exercise, myo-inositol 4g per day which has strong mechanistic support for improving insulin signaling in ovarian tissue specifically, and berberine 500mg three times daily if lifestyle modifications alone are not moving the number.

This is one of the highest-yield metabolic assessments missing from most fertility workups. And unlike many of the variables involved in IVF outcomes, this one responds directly to lifestyle-level interventions in a measurable timeframe.

If nobody has ever ordered a fasting insulin alongside your fasting glucose, you have not had a complete metabolic fertility assessment.

Want to understand what a full metabolic investigation would look like for your situation? Schedule a logistics call to learn how the OVAHaul Analysis approaches this.

Schedule a Call Here

With you every step,

Lindsay Chu

Founder of OVAHaul
Clinical Embryologist

If your embryology report has ever included the note smooth ER clusters observed, you probably were not given much explanation of what that means. Most patients are not. This newsletter is going to change that.

Smooth endoplasmic reticulum clusters, called SERc, are abnormal cytoplasmic inclusions found inside the oocyte. They indicate that the calcium storage and release system within the egg is dysregulated and that the endoplasmic reticulum is under stress. They appear in 2 to 5% of mature eggs retrieved in IVF cycles and are associated with altered calcium oscillation patterns at fertilization and higher chromosomal abnormality rates in the embryos they produce.

Here is the part that matters most: they are more common in cycles where FSH stimulation was excessive.

This is the connection that most patients are never told about. The drive to retrieve more eggs, achieved by pushing stimulation higher, can compromise the quality of what is inside those eggs. Overstimulation creates an intrafollicular environment where calcium store regulation is disrupted. SERc oocytes are one measurable outcome of that disruption.

This does not mean that a SERc finding makes an embryo worthless. It means that embryo carries a higher risk of chromosomal abnormality and should not be the first choice for transfer without genetic screening. PGT-A on any SERc-origin blastocyst, if available, is the recommended pathway to identify whether there are euploid embryos within that group.

The prevention conversation is equally important. If you have had prior SERc findings, a mild stimulation protocol in your next cycle is clinically indicated. The goal is quality of the follicular environment, not maximum follicle count. A clinic that responds to a DOR diagnosis by simply increasing FSH doses may be moving in the wrong direction for your specific biology.

The SERc finding is also a piece of information about your ovarian response to stimulation that belongs in the conversation before your next cycle begins. Not as a reason for alarm, but as a data point that informs how the next protocol should be designed differently.

Your embryology report contains more information than the summary you receive. Knowing how to read it changes what questions you bring to your next consultation.

Interested in understanding what your full embryology history might be telling you? Schedule a logistics call to learn how OVAHaul reads between the lines of your IVF data.

Schedule a Call Here

With you every step,

Lindsay Chu

Founder of OVAHaul
Clinical Embryologist

Day 3 looked hopeful. And then day 5 came and there was nothing.

If this has happened to you more than once, I want you to know that the absence of an explanation is not the same as the absence of a cause. Getting to day 3 and failing to reach blastocyst is a specific biological failure with documented mechanisms. It just requires asking the right questions.

To become a blastocyst, your embryo has to complete two sequential structural events that are each biologically demanding in their own way.

The first is compaction. On day 4, the cells of the embryo have to press together tightly and form a structure called the morula. This requires the cells to express a protein called E-cadherin and build a network of tight junctions between themselves. If E-cadherin expression fails, or if the maternal RNA stores that drive that expression are depleted, the cells stay loosely arranged and compaction does not happen.

The second is cavitation. The embryo has to pump fluid into its center to build the fluid-filled cavity that defines a blastocyst. This requires aquaporin 3 channels and Na/K-ATPase ion pumps to be functioning. If they are not, or if the culture environment is not supporting this metabolically intensive process, the blastocoel never forms.

Both events can fail independently. And both have specific, investigable causes.

Chromosomal errors are one driver. Maternal RNA depletion is another, more common in women over 38 and in diminished ovarian reserve patients. In young patients with no chromosomal explanation and repeated compaction failure, a maternal effect gene panel looking at TLE6 and PADI6 is clinically indicated. These are genes required for compaction and they represent a distinct genetic category of embryo developmental failure.

And then there is the culture environment.

The composition of the culture media your embryos are developing in, specifically its glucose, amino acid, and growth factor concentrations, directly affects the metabolic processes required for compaction and cavitation. This is not theoretical. A 2025 paper in Human Reproduction Open showed that different commercial media brands produced meaningfully different developmental outcomes. And the oxygen tension in the incubator matters enormously: multiple RCTs confirm that 5 to 8% oxygen, matching the physiological environment, improves blastocyst rates compared to atmospheric oxygen. ESHRE and ALPHA designate low-oxygen culture as a non-negotiable quality standard.

These are questions you are allowed to ask your clinic. What media brand do you use? What oxygen tension? Have you changed either in the past two years?

The answers tell you whether the lab environment is working with your embryos or against them.

Not reaching blastocyst is not the end of the investigation. It is the beginning of a more specific one.

Want to map what an investigation would look like for your embryo development history? Schedule a logistics call to talk through the OVAHaul Analysis.

Schedule a Call Here

With you every step,

Lindsay Chu
Founder of OVAHaul
Clinical Embryologist

Sources: Fierro-Gonzalez 2013; MEG/TLE6/PADI6 STRONG; Kleijwegt 2025 Hum Reprod Open; Kovacic 2010 Cochrane

When high embryo fragmentation shows up cycle after cycle, the instinct is to try harder on the preparation side. More supplements. Stricter diet. Better sleep. And while those things matter, repeating the same approach without understanding which mechanism is driving the fragmentation means the pattern is likely to repeat too.

Fragmentation is not one problem. It is four distinct biological problems that happen to produce the same visible result in the embryology report.

The first mechanism is oxidative stress triggering the apoptotic pathway inside the oocyte. When the oocyte’s antioxidant defenses are overwhelmed during the weeks before retrieval, programmed cell death pathways become activated in the developing embryo. The second is mitotic spindle errors from chromosomal instability: when chromosomes do not segregate correctly during cell division, the mechanical stress creates fragmentation. The third is cytoskeletal disruption from toxin or chemical exposure in the follicular environment, including endocrine-disrupting compounds that interfere with the structural proteins holding blastomeres together. The fourth is oocyte cytoplasmic immaturity from premature triggering, where the egg was retrieved before the cytoplasm finished its developmental preparation, regardless of how mature it looked on ultrasound.

Each one of these mechanisms requires a different investigation and a different intervention. Treating all four with the same CoQ10 and diet protocol is like treating four different infections with the same antibiotic.

Here is how to start telling them apart.

Timing matters. Fragmentation that begins before day 2 typically points toward oocyte-origin issues, meaning mitochondrial function and cytoplasmic maturity. Fragmentation that appears at day 3 or later often points toward genome activation failure, the same MZT problem discussed in the previous newsletter. This timing information is visible on time-lapse monitoring if your clinic uses it, which is a question worth asking.

The investigation questions to bring to your next consultation include these: what was my trigger timing relative to follicle development, and was there any concern about premature LH surges? What is the oxygen tension in your culture system? What media brand are you using? Can I see the time-lapse data from my last cycle?

The supplement protocol for oocyte-origin fragmentation does have evidence behind it. CoQ10 600mg per day and melatonin 3mg at bedtime for a minimum of 3 months before retrieval are the evidence-based starting points. But supplementing without knowing which mechanism is driving the fragmentation is optimizing in the dark.

Your embryos fragmented for a reason. Finding that reason is the work.

Ready to investigate which system is driving your pattern? Schedule a logistics call to learn how the OVAHaul Analysis approaches fragmentation workup.

Schedule a Call Here

With you every step,

Lindsay Chu
Founder of OVAHaul
Clinical Embryologist

Sources: Otsuki 2004; Ebner 2008; Kovacic 2010 Cochrane; ESHRE/ALPHA 2018

If your IVF cycles have involved fertilization followed by very early arrest, and the focus of investigation has been exclusively on you, this newsletter is for you and your partner to read together.

Here is a finding that the research has documented for over a decade but that almost never makes it into a standard fertility consultation: sperm can be entirely responsible for early embryo arrest while every metric on the semen analysis looks completely normal.

The protein at the center of this is called PLCZ1. Phospholipase C zeta.

After ICSI, the sperm carries one job beyond delivering the paternal DNA: triggering the calcium signal that wakes the egg up. Fertilization is not a passive event. After the sperm enters the oocyte, PLCZ1 initiates a series of calcium pulses inside the egg, typically 10 to 12 over about 4 hours. These calcium oscillations are the biological signal that tells the egg it is time to exit its arrested state and begin dividing. Without them, the egg receives no activation signal. Fertilization technically occurred. But the embryo never properly starts.

PLCZ1 deficiency produces a very specific clinical pattern. ICSI fertilization is confirmed. The embryo arrests at the 1 to 4 cell stage. This happens across multiple cycles. And the semen analysis remains normal on every repeat.

The reason this matters so much is that without knowing PLCZ1 is the issue, the treatment pathway is entirely wrong. Changing her protocol, adding more supplements to her preparation, adjusting the stimulation approach. None of that addresses the actual problem.

The test for PLCZ1 is immunofluorescence of the sperm protein expression, available at specialist andrology labs. The treatment is artificial oocyte activation, or AOA, using calcium ionophore A23187 in the minutes following ICSI. Published data shows fertilization rates improving from under 20% to 50 to 80% in confirmed PLCZ1-deficient cases. Safety data is reassuring to age 3 to 5 years.

This is not a rare edge case that applies to a tiny fraction of couples. Normal semen analysis with unexplained early embryo arrest is a clinical presentation that points directly toward sperm functional testing. That testing is almost never ordered in a standard fertility workup.

If your cycles have looked like this, the conversation about sperm function needs to happen before your next retrieval.

The investigation has to go further than the standard panel. Both of you deserve that.

Want to understand what a full OVAHaul Analysis would look like for your specific situation? Schedule a logistics call and let’s talk about what hasn’t been investigated yet.

Schedule a Call Here

With you every step,

Lindsay Chu
Founder of OVAHaul
Clinical Embryologist

Sources: PLCZ1 2011-2023 STRONG mechanism; Hiraoka 2018 AOA safety; EMERGING clinical data

Let’s talk about something that doesn’t get explained nearly enough: why embryos arrest on day 3.

You did everything right. Your follicles responded. Fertilization happened. And then the lab called on day 3 and said they didn’t make it. And when you asked why, the answer was something vague about embryo quality or chromosomes.

That answer is incomplete. And you deserve better than incomplete.

Here is what is actually happening at day 3.

Your embryo has been running on stored resources since the moment of fertilization. Everything it needed to get through those first few days was already loaded into the egg before retrieval: maternal RNA, mitochondrial machinery, energy reserves. At the 8-cell stage, something critical has to happen. The embryo has to switch from running on your stored resources to activating its own genome for the very first time. Scientists call this the maternal-to-zygotic transition, or MZT.

This transition is energetically expensive. It requires a functioning mitochondrial system inside the oocyte to generate enough ATP to drive the switch. If that energy system was running at reduced capacity, the embryo reaches the moment of genome activation and simply cannot complete it. Development stops. Not because of a chromosomal problem. Not because of age alone. Because of the energy supply inside the egg itself.

What determines that energy supply? The 90 days before your retrieval.

The mitochondrial capacity of your oocyte is shaped by the follicular environment it developed in over the three months leading up to your egg collection. Oxidative stress inside the follicle depletes the antioxidant protection the oocyte depends on. CoQ10 availability directly supports the electron transport chain inside mitochondria. Inflammatory markers circulating in your system reach the follicular fluid and affect the biochemical environment your egg is maturing in.

This is not abstract. This is measurable. And more importantly, it is modifiable.

The research that matters here is building consistently across multiple papers: mitochondrial dysfunction in oocytes is a primary driver of poor embryo development, and the 90-day pre-retrieval window is the intervention window because that is how long it takes for a primordial follicle to mature into the egg you will retrieve in your next cycle.

The specific variables to investigate before your next retrieval include CoQ10 status, melatonin as an intrafollicular antioxidant, GGT as a proxy for hepatic oxidative stress and glutathione depletion, inflammatory markers, and stimulation protocol relative to signs of cytoplasmic maturity. These are not the same as the standard monitoring bloodwork you receive during a cycle. They require a different lens entirely.

If your embryos have arrested at day 3 and the explanation stopped at egg quality, the investigation has not gone far enough.

Your body is not broken. The investigation was incomplete.

Ready to find out what else might be going on in your specific biology? Schedule a logistics call to learn how the OVAHaul Analysis investigates the systems behind your cycle outcomes.

Schedule a Call Here

With you every step,

Lindsay Chu

Founder of OVAHaul
Clinical Embryologist

Sources: Latham 2015; Schulz 2019; Miao 2021 Cell Reports

A ten years ago, I sat in an OBGYN office with a list of questions I had been building for months. My cycles had gone irregular. Six months before that, I had a miscarriage. I had been paying attention to my body long enough to know something had shifted. I wasn’t spiraling. I was just paying attention. And I wanted someone to pay attention with me.

The appointment was 15 minutes.

I walked out with a birth control prescription and the words “everything looks good.”

I sat in my car and I just stared at the steering wheel. Because nothing felt good. Nothing looked good to me. And I knew, in the way that you know things about your own body before anyone else does, that I had walked in looking for answers and walked out with something that wasn’t one.

Here’s what I wasn’t told.

Birth control depletes folate, B6, B12, zinc, magnesium, and CoQ10. Those are not random nutrients. Those are the exact building blocks your eggs need to mature properly, to support fertilization, to sustain early embryo development. Research published in the Journal of Clinical Endocrinology and Fertility and Sterility has documented these depletions for years. Folate is critical for DNA methylation and cell division in the early embryo. CoQ10 is the fuel source for the mitochondria inside your eggs. Zinc is involved in every stage of folliculogenesis. B6 and magnesium are essential for progesterone synthesis and luteal phase support.

None of that was in the room with us.

What was also not in the room: the honest truth that birth control does not fix irregular cycles. It pauses them. It is a pause button dressed up as a solution. And when you come off it, your body will pick up right where it left off. The root cause will still be there, waiting.

I was not told that. I was told my labs were fine, handed a prescription, and sent home.

I know I am not the only person who has sat in that car.

So I did what I have always done when I don’t get an answer. I went looking for one myself.

That search became a Master’s degree in Reproductive Clinical Science at Eastern Virginia Medical School. And then a career as a clinical embryologist, spending years inside the IVF lab with my hands in the work. I understood the science better than I ever had. And the patients were still getting vague answers.

Women were coming through IVF cycles being tested for the process, not for what was actually happening in their bodies. I kept finding things in the research I could not stop asking about. I would bring them to my lab manager: what about this marker, what if we tested this, I found this study. He would hear me out and then say, “that’s not our job. Our job is IVF.”

That answer left something very specific in my chest. Fury. And direction.

This is why I built OVAHaul.

Because “everything looks normal” is not the same as everything being okay. Because the fertility workup most women receive before and during IVF was designed to check reproductive anatomy, ovarian reserve, and semen parameters. That is the minimum. It is not an investigation. It does not look at your mitochondrial function, your coagulation factors, your thyroid antibodies, your inflammatory markers, your nutrient status, or any of the other systems that research has consistently linked to cycle quality, implantation success, and embryo development.

The investigation gap is real. I have seen it from both sides now. As a patient sitting in that car with a now 3 year old, and as a clinician standing inside the lab watching it happen in real time. And I built everything at OVAHaul around closing it. For me. And for you.

Over the past six months, I have had so many conversations with you. Real ones. About your labs, your protocols, your history, your questions that never got answered. Through those conversations, you showed me something I needed to see.

For some of you, the OVAHaul Analysis or the 3-Month Program is exactly the right fit. That deep, full-system investigation is what you need, and that work is some of the most meaningful I do. If that’s you, those programs are still here.

But not everyone is in that place right now. Some of you are mid-cycle. Some of you are in a holding pattern, trying to figure out your next step. Some of you aren’t ready for a full deep dive. But you are absolutely done doing this alone, without a framework, without someone in your corner who speaks the science fluently and can help you make sense of what is happening in your body.

I heard you. And I have been building something for exactly that.

The OVAHaul Membership.

This is not a Facebook group. This is not a wellness community with good vibes and vague advice. This is clinical education, real science, and genuine support, built for women who are done guessing and ready to investigate.

It runs on the same 10-systems framework I use in every OVAHaul Analysis. Hormonal. Immune. Metabolic. Mitochondrial. Coagulation. Chromosomal. Gut. Thyroid. Nutritional. Nervous system. Because your fertility is not one system. It is all of them talking to each other. And when something is off, you deserve to know which room the noise is coming from.

This is for you if:

• You have been told everything looks normal but something still feels off.

• You left your last appointment with more confusion than you walked in with.

• You have been handed a protocol with no explanation of why.

• You have sat in appointments not knowing what to ask, or feeling like your questions were too much.

• You have taken the supplements, changed what you eat, rearranged your entire life. And you still don’t know if it’s working.

• You want to understand what your labs actually mean. You want to know if you need deeper testing.

• You believe your body is trying to tell you something.

• You are ready to investigate. Not just wait, and hope, and hear “let’s try again.”

• You want support that is both scientific and human.

When you join, you get access to:

• Clinical curriculum built by an embryologist and reproductive clinical scientist. Not wellness content. Not generic fertility advice. The actual science, taught in a way that makes it yours to use.

• Monthly live case reviews. Real labs, real cases, walked through in real time so you can start applying the same thinking to your own situation.

• Monthly guest expert roundtables. Specialists in reproductive immunology, metabolic health, thyroid function, and integrative medicine. The voices that go deeper than a 15-minute appointment allows.

• A private members-only podcast. Long-form science, on your schedule, for your ears only.

• Protocol tracker and lab reference cards. So you know what your numbers mean and whether your protocol is actually responding to your biology.

• Before-your-appointment prep guide. So you walk in with the right questions and leave with actual answers.

• The Investigation Cohort community. A private space full of women who are serious about understanding their bodies. Not a place to vent without direction. A place to investigate together.

• Fertility Kitchen recipe bank. Nutrition built around the science of egg quality, uterine lining health, and hormonal regulation. Not generic clean eating.

• Movement by Cycle Phase video library. Exercise programming built around your hormonal biology, not against it.

• A new course every single month. This curriculum grows. It will keep growing.

We are opening the Founding Cohort first.

Founding members get exclusive pricing, early access, and benefits that won’t be available once we open publicly. Spots are limited intentionally. I want this first group to be close.

And here’s what I want you to know: joining the waitlist is not a commitment. It is just a way to tell me you’re interested, and to answer a few short questions so I can make sure this membership actually meets you where you are. That is it. I will send you more information as we get closer to opening, and you can decide from there.

I have so much I want you to know. About your labs. About your cycle. About what the research actually says about what you can do to investigate and optimize before your next one. I have been holding all of this and I cannot wait to share it with you.

This community is for the woman who walked out of an appointment and sat in her car knowing something was being missed.

I see you. I was you. And I built this for both of us.

Join the waitlist here. It takes two minutes and it is completely free.

I’m in. Add me to the waitlist. →

With you every step,

Lindsay Chu

Clinical Embryologist | MS Reproductive Clinical Science | Founder, OVAHaul

OVAHaul is an education and investigation platform. It is not a medical practice and does not replace the care of your reproductive endocrinologist or healthcare provider.

Birth control is also used in IVF sometimes to help sync follicles for your cycle.

But I want to dive in deeper here because a lot of time we are given this “tool” but not given a strategy.

Last month I sat in my OBGYN’s office and described what had been happening with my cycle since my chemical pregnancy in November. Irregular timing. A body that felt like it was still searching for its rhythm. I wanted to understand what was going on hormonally and what I could do to support my system before trying again.

The answer I got was a prescription for birth control.

“Turn everything off. Let it reset.”

I sat in my car afterward and thought about how many women receive this exact recommendation, take that prescription, and never get told a single thing about what happens to their body while they are on it or when they come off.

I am a clinical embryologist. I have spent years in the IVF lab watching what happens to eggs and embryos at the cellular level. I started OVAHaul because I believe the standard fertility workup misses most of what actually determines whether your eggs are healthy and whether your embryos will implant. And I will be honest with you: even I had to sit in that office and push past the feeling that the prescription was the end of the conversation.

We will talk about what I am actually doing to support my hormones and heal from a chemical pregnancy in a future issue. That conversation deserves its own space. But today I want to start with what that appointment made urgent for me:

If you are using hormonal birth control as a fertility tool, you need a strategy. And most women are not being given one.

This Is Not Anti-Pill

Let me be direct before we go any further.

Oral contraceptives are among the most studied drugs in history. They are effective, widely used, and for many women, the right choice for a range of reasons including cycle scheduling before IVF, managing endometriosis, reducing androgen symptoms in PCOS, or preventing pregnancy during a time when it is genuinely not right.

This is not asking you to stop taking birth control.

What it is asking is whether anyone has ever told you what birth control does to the nutritional environment your eggs develop in. Because that part of the conversation almost never happens in the fifteen minutes you get with your provider.

What Is Happening to Your Eggs While You Are on the Pill

This is where I talk about eggs, so stay with me.

Your oocytes do not mature overnight. The follicle that releases an egg at ovulation started its journey roughly three months earlier as a small antral follicle. During that entire growth window, the egg is completely dependent on the fluid surrounding it inside the follicle for its nutritional environment. That fluid, called follicular fluid, reflects what is circulating in your body. Whatever you are depleted in, your eggs are depleted in.

Here is what the research consistently shows gets depleted in women using combined oral contraceptives.

Folate. This is the most studied depletion and the one I think about most from an egg quality standpoint. Folate is not just a prenatal vitamin requirement. Inside the follicle, it is a direct regulator of homocysteine clearance. Homocysteine is a metabolic byproduct that, when it accumulates in follicular fluid, impairs the methylation processes that control how your egg’s chromosomes are packaged and segregated during meiosis. A 2009 IVF cohort found that no pregnancies occurred from follicles with elevated homocysteine levels, even when blood levels looked completely normal.

Folate levels take approximately three months to normalize after stopping OCPs. This means the eggs you ovulate or retrieve in the months immediately after stopping the pill developed in a folate-depleted follicular environment.

Vitamin B12 and B6. Both co-factors in the same homocysteine-clearing pathway. B12 is required to convert homocysteine back to methionine. B6 supports the backup detox route. Both are consistently lower in OCP users. Subclinical B12 depletion is especially easy to miss because standard serum labs do not capture what is happening at the follicular level, and there is direct evidence that optimal B12 inside the follicle independently affects oocyte maturation rates, fertilization, and blastocyst progression.

CoQ10. A controlled study measuring CoQ10 and total antioxidant capacity in users of oral pills, the vaginal ring, and the transdermal patch found that all three significantly reduced CoQ10 levels compared to non-users.

From an embryology perspective, this is the one that keeps me up at night. The oocyte is the most mitochondria-dense cell in the human body. It carries an estimated 100,000 to 300,000 mitochondria because all the energy required to complete meiosis, extrude the polar body, align the chromosomes on the spindle, and support the first days of embryo development comes entirely from maternal mitochondrial function. CoQ10 is the rate-limiting electron carrier in that entire system.

When CoQ10 is low, mitochondrial ATP output falls. When ATP falls, the precision required to segregate chromosomes cleanly is compromised. This is one of the most mechanistically coherent explanations for embryo aneuploidy, and it is directly relevant to anyone coming off birth control.

Zinc and Selenium. Both lower in OCP users, proportional to duration of use. Zinc is required for the oocyte’s final maturation step and for the fertilization process itself. Follicular fluid zinc concentration directly correlates with MII oocyte count and fertilization rate in IVF data. Selenium drives the glutathione peroxidase enzymes that protect your egg from oxidative damage during the most vulnerable phase of its development.

Vitamin D. This one runs the other direction. OCP users tend to have higher vitamin D while on the pill because estrogen increases the binding protein that carries it in circulation. The clinical problem is the drop that happens when you stop. Women transitioning off birth control before IVF or natural conception often enter their most critical fertility window in a newly vitamin D-deficient state while simultaneously depleted in everything else.

What This Means If You Are Using Birth Control Before IVF

The use of oral contraceptives before IVF to schedule a cycle or suppress a dominant follicle is common practice. But whether it helps your outcomes is a more nuanced question than most patients are told.

For normoresponders in a well-managed cycle, OCP pretreatment is largely neutral. But two contexts make the picture meaningfully worse.

First, protocol type matters. A 2025 meta-analysis of over 4,400 women with PCOS found that OCP pretreatment before a GnRH antagonist protocol was associated with a higher miscarriage rate and lower live birth rate compared to no pretreatment. The combination of OCP suppression followed by antagonist protocol appears to create an LH environment that is too suppressed for complete oocyte maturation. The same analysis found no significant difference when OCP pretreatment preceded a GnRH agonist long protocol. If your clinic recommends OCP before IVF, asking which protocol follows it is a legitimate and important question.

Second, progestin formulation matters. Data from egg donor cycles found that donors on higher-androgenicity progestins had significantly lower oocyte yields compared to donors on lower-androgenicity formulations or no contraception. Donor data is worth paying attention to because it isolates the contraceptive variable from the underlying diagnosis.

The Post-Pill Window

If you are coming off birth control to try to conceive or to prepare for a retrieval cycle, here is what the data actually supports.

AFC suppression is real and reversible. A UCSF longitudinal study of 743 women found that 70% of long-term OCP users had a lower antral follicle count than expected for their age. Women who took a 4 to 6 month break before retrieval recovered an estimated 6.7 additional oocytes compared to those with no break. A 7 to 9 month break was associated with 9.2 additional oocytes. AFC improvement began within the first month and plateaued around 6 to 7 months post-pill.

AMH should not be measured too soon. A 2025 Weill Cornell study found AMH levels rose significantly between 9 and 16 weeks after stopping OCPs. If your AMH was tested within the first few weeks off the pill and the number scared you, test again after week 12 before drawing any conclusions about your reserve.

For repletion timelines, the evidence supports:

Folate: approximately 3 months to normalize, which maps onto the follicular growth window directly. Start methylfolate, not folic acid, especially if you carry an MTHFR variant.

CoQ10: 60 to 90 days minimum to achieve meaningful mitochondrial benefit. Use ubiquinol if you are over 35.

Methylcobalamin and P-5-P: same 60 to 90 day window. These are the active forms. Cyanocobalamin and pyridoxine require additional enzymatic conversion that is genetically variable.

Zinc, selenium, and magnesium: 60 plus days. Normalizing serum levels is not the same as accumulating adequate concentrations in follicular fluid, which is what your egg actually has access to.

The Part Nobody Says Out Loud

None of what I described above is fringe science. The research on OCP-induced micronutrient depletion spans over five decades. The connection between follicular fluid nutrient status and IVF outcomes is well-established in the reproductive biology literature. The mechanistic link between what you are depleted in and what your embryos do on day 5 is something I have watched play out in the lab.

What is missing is that this information almost never makes it into the room where prescriptions are written.

The woman told to go on birth control for two months before IVF does not receive a supplement protocol. The woman told she can start trying the month she stops the pill is not told that her folate stores are depleted and her CoQ10 is lower than it should be and her antral follicle count may not reflect her true reserve for several more months.

She is just handed a prescription and sent home.

I understand why. Appointments are short. Standard protocols work for a lot of people. But for the woman who is already doing everything right and still watching cycles fail, the question of what her prior birth control use did to her follicular environment is worth asking out loud.

That is what OVAHaul is here for.

What to Do With This

You do not need to overhaul everything tomorrow. You need a strategy.

If you are currently on birth control and planning IVF or TTC in the next year, start a prenatal with active B vitamins now. Methylfolate and methylcobalamin, with folic acid as well. Add CoQ10. Ask your provider which stimulation protocol follows your OCP pretreatment and why.

If you recently came off the pill, do not treat AMH or AFC numbers from the first 8 weeks as definitive. Give your body the repletion window the research supports before making decisions based on those numbers.

If your labs look normal but your cycles still feel off, remember that serum levels and follicular fluid levels are not the same thing. Your blood does not tell the whole story. Your egg’s environment does.

You deserve to know what is in it.

With you every step,

Lindsay Chu, MS | Clinical Embryologist | Founder, OVAHaul

Www.ovahaul.com | @lindsayatovahaul

So we’re fixing that.

Starting this Friday, I’m sending you a curated roundup of the latest fertility research — the studies that actually move the needle. No fluff, no fear, just the science that’s worth knowing, translated into something you can actually use.

Welcome to Fertility Friday.

And I mean it when I say I want to hear from you. The good, the bad, all of it. Where you are in your journey, what questions you can’t get answered, what’s keeping you up at night. Reply to this email and it comes straight to me. I am cheering for every single one of you across this screen, and I don’t take lightly that you let me into this part of your life.

This is your journey. I’m just here to help you navigate it.

ONE MORE THING

OVAHaul has been continuously growing — and this summer, we’re expanding in some new ways I am really excited about. I’ve been listening to your feedback, and I think this next step is going to be exactly what so many of you have been asking for.

More details coming soon, but just know: it’s being built for you.

With you every step,
Lindsay Chu
Founder of OVAHaul

And your clinic said some version of: this happens sometimes. We will try again.

That answer is not enough. And deep down, you already know that.

Here is what I want you to understand: the stage at which your embryo arrested is not random. It is mechanistically specific. It is your body communicating something precise about what failed, at what moment, in what system. The problem is that most clinics do not have the time, the framework, or the mandate to translate that signal into an investigation.

That is exactly what OVAHaul exists to do.

The stage is the clue.

Day 3 arrest points toward the paternal genome. Around Day 2 to 3, your embryo has to switch from running on your RNA to activating its own genes. That activation starts with the father's DNA. If his sperm carries DNA fragmentation, chromatin damage, or oxidative injury, that activation fails. The embryo stalls. The clinic calls it poor embryo quality. The actual culprit is testable. A Day 3 arrest can also point towards metabolic or inflammatory pathways.

Day 5 arrest, or failure to reach blastocyst, points toward metabolism. At the morula-to-blastocyst transition, the embryo makes a sharp metabolic switch. It stops running on pyruvate and starts running on glucose. If your insulin signaling is dysregulated, even subtly, the environment your embryo develops in cannot support that switch. A HOMA-IR of 2.4 is within normal range. It is also associated with significantly lower blastocyst formation rates in the research.

Fertilization failure points toward sperm oxidative stress, specifically a protein called PLCzeta, which is the activation signal the sperm delivers to your egg. If it is damaged or absent, the egg never starts dividing. This is testable. Calcium ionophore activation has strong data for rescue.

OVAHaul maps your specific pattern to the upstream systems most likely responsible. Then we investigate those systems with targeted bloodwork. Not a generic panel. The specific markers the research connects to your pattern.

Every marker in our panels has peer-reviewed literature behind it. Every cutoff we use is fertility-specific, not the standard lab range built for a general population.

What we look at.

Our Women's Core Panel covers reproductive hormones, ovarian reserve, thyroid function and autoimmunity, metabolic health, one-carbon metabolism, micronutrient status, and a baseline immune screen. It is the foundation of every investigation.

From there, we go deeper based on your pattern. The Oxidative Stress and Mitochondrial Panel. The Methylation Depth Panel. The Immune Regulation Panel. The Thrombophilia Panel. Each one targeted. Each one mechanistically connected to what your history is telling us.

We do not run everything on everyone. We map your pattern first. Then we investigate the systems most likely to explain it.

If your embryos have arrested and you want to understand what your data is actually telling you, that conversation starts with a logistics call.

Schedule a Logistics Call with Lindsay

With you every step,

Lindsay Chu
Founder of OVAHaul

If you have been following the fertility science space, you have probably seen the headlines. Microplastics in blood. In breast milk. In placentas. In the ocean, the air, the food supply. The headlines keep coming and they keep getting worse.

What most of them never get to is the part that actually matters for fertility warriors: what microplastics are doing inside the specific biological environment where fertility lives. The follicular fluid. The granulosa cells. The endometrium. The hormonal signaling that governs every step of ovulation, fertilization, and implantation.

That is what this issue is about.

The research published in 2024 and 2025 represents a real shift in the science — from “plastic might be bad for us” to “plastic is confirmed inside reproductive tissue and here is what it is doing at the cellular level.” As a clinical embryologist who spent years watching embryo development under a microscope, I can tell you that the mechanisms being described in this literature are not abstract. They are the exact pathways that determine whether an egg matures, whether it fertilizes, whether an embryo develops the way it should, and whether it implants.

This is a longer read than usual. It is meant to be. Save it. Come back to it. Share it with your care team if they are not asking these questions yet. The investigation into what is actually disrupting your fertility does not stop until we have looked at the whole system.

Here is what the research shows.

THEY FOUND IT INSIDE THE FOLLICLE

The question researchers have been working to answer is not whether we are exposed to microplastics. That question was settled years ago. The question is whether particles are reaching the tissues that matter most for fertility, and whether they are doing measurable biological damage when they get there.

In 2025, Montano and colleagues published the first confirmed detection of microplastics in human ovarian follicular fluid. This is not peripheral tissue. Follicular fluid is the direct microenvironment of the developing egg. It surrounds the oocyte, delivers nutrients, and carries the hormonal signals that guide maturation. Finding microplastics here is the reproductive equivalent of finding a contaminant in the amniotic fluid.

Their team found detectable particles in 14 of 18 IVF patients tested. That is 78%. The average concentration was 2,191 particles per milliliter. The dominant polymer types were exactly what you would expect from a population exposed to modern consumer goods: polyethylene, polypropylene, polystyrene, PVC, and PET. The same plastics in your food containers, your water bottle, your packaging. The mean particle diameter was 4.48 micrometers, which is small enough to be taken up by cells.

A second 2025 study from Zhejiang University went further and asked a question that matters clinically: is the amount of microplastic in follicular fluid related to ovarian reserve? They compared 25 women with a diminished ovarian reserve diagnosis to 20 women with normal reserve. Microplastics were present in 100% of samples in both groups. But the women with DOR had 65% higher concentrations — 30.63 micrograms per gram versus 18.48 in controls. Polyethylene and PVC concentrations showed the strongest negative correlation with AMH levels and antral follicle count.

Yan and colleagues (2024, Environment International) found something even more direct in a cohort of 44 women undergoing assisted reproduction: polyethylene concentration in follicular fluid showed a statistically significant negative correlation with fertilization rates. The correlation coefficient was -0.407 with a p-value of 0.007. These were not women selected for high plastic exposure. This was their ambient microplastic load, measured from the fluid already present in their follicles during an active IVF cycle.

Beyond the ovary, microplastics have now been confirmed in human endometrial tissue, in uterine fibroids at concentrations higher than the surrounding myometrium, and in all 22 uterine samples from women with recurrent miscarriage studied in a 2024 Environmental Science and Technology paper. The picture forming from this collective evidence is of a reproductive system that has already been penetrated at every level — and research that is only beginning to map what that means for outcomes.

THE HORMONE HIJACK

Microplastic particles do not arrive alone. Their surface acts as a magnet for environmental pollutants, adsorbing pesticides, heavy metals, and persistent organic compounds from wherever they have traveled before reaching your tissue. Researchers call this the Trojan horse effect: you ingest one particle and receive an entire payload of co-contaminants, delivered directly into the environment surrounding your eggs.

The chemical cargo is where the endocrine disruption story lives. BPA, phthalates (DEHP, DBP), PFAS, flame retardants, and UV stabilizers all leach from the polymer matrix into surrounding tissue. A landmark 2011 analysis found that over 95% of commercial plastic products leach chemicals with measurable estrogenic activity after normal use — including products labeled BPA-free. The BPA alternatives BPS and BPF bind the same hormone receptors with comparable or greater potency in several cell models. The label is not the data.

These chemicals bind estrogen receptors ERa and ERb, androgen receptors, and critically, the membrane receptor GPR30, which responds to some plastic chemicals with effects comparable to natural estradiol at nanomolar concentrations. At the cellular level in granulosa cells, they suppress StAR protein, which handles cholesterol transport into the mitochondria. They suppress aromatase, which synthesizes estrogen. They suppress CYP11A1, which is the first enzymatic step in all steroid hormone production. The hormonal signature this produces in animal models is remarkably consistent: decreased estradiol, decreased progesterone, decreased AMH, elevated FSH. That profile should sound familiar to anyone who has reviewed a fertility panel.

There is one more piece to the endocrine story that standard toxicology is not designed to catch. These chemicals do not follow a linear dose-response curve. At very low concentrations, some of them — BPA in particular — paradoxically stimulate estrogen production. At higher concentrations they suppress it. This non-monotonic dose response means there is no safe threshold that standard safety testing can identify. The effect at a low, environmentally realistic dose cannot be predicted from a high-dose study. We are all living inside an experiment that was never designed with a control group.

WHAT IS HAPPENING TO THE EGG ITSELF

Your eggs have more mitochondria than almost any other cell in the human body. This is not incidental. Completing meiosis, extruding a polar body, and assembling a functional spindle during fertilization are among the most energetically demanding processes in biology. When mitochondrial function is compromised, those processes fail in specific and measurable ways.

The single most consistently replicated finding across all microplastic reproductive toxicology research is a massive surge in reactive oxygen species accompanied by collapse of the antioxidant defense system. Studies consistently find decreased glutathione, decreased SOD, and decreased catalase in exposed ovarian tissue. The mitochondria themselves show abnormal morphology. Membrane potential drops. Energy production decreases. Polar body extrusion rates fall. Spindle defects increase. Chromosome misalignment increases.

The practical translation: when an egg’s mitochondria are not functioning correctly, the egg is more likely to have an abnormal spindle, more likely to have chromosome segregation errors during fertilization, and more likely to produce an aneuploid embryo. Higher microplastic load in the follicular environment correlates directly with lower fertilization rates in the human data we have.

The epigenetic layer adds another dimension that the field is only beginning to characterize. Microplastic exposure has been shown in fish studies to produce DNA methylation changes in genes related to inflammation, reproductive signaling, and estrogenic pathways — and those methylation changes were inherited by offspring who were never directly exposed. The same pattern held through F1, F2, and F3 generations in C. elegans. We do not yet have large mammalian or human data confirming transgenerational inheritance of microplastic-induced epigenetic damage. The research does not exist because the field is that new. But the animal signal across multiple species is consistent and the mechanism is understood.

For Fertility Warriors in a preconception window: egg quality reflects the last 90 days of cellular environment. The methylation marks your eggs carry reflect the cumulative chemical environment of your reproductive system over time. This is not a reason for panic. It is a reason for investigation.

THE IMMUNE SYSTEM AND IMPLANTATION

When your body encounters a foreign particle in tissue, the immune system responds before any other system does. Microplastics activate TLR2 and TLR4 pattern recognition receptors, triggering NF-kB — your master inflammatory switch — and the NLRP3 inflammasome. The result is a cytokine cascade: elevated IL-1 beta, IL-6, and TNF-alpha in reproductive tissue.

This matters acutely for implantation because successful embryo attachment requires one of the most precisely calibrated immune environments in the human body. It needs to be slightly pro-inflammatory at the moment of implantation to allow trophoblast invasion, and then it needs to shift to anti-inflammatory to protect the developing conceptus as it grows. Microplastic-driven chronic immune activation disrupts both phases. A 2025 study showed oral microplastic exposure in mice impaired uterine receptivity through NLRP3 and TLR4 activation. Decidual natural killer cells were altered. Macrophage polarization shifted. Embryo resorption rates increased.

For women navigating recurrent implantation failure or recurrent pregnancy loss where the standard workup has come back normal, this immune disruption pathway is a dimension of the investigation that is rarely considered. The connection to endometriosis and PCOS is also emerging: women with endometriosis show higher microplastic concentrations in their urine with a different polymer profile than healthy controls, and daily polystyrene ingestion in a zebrafish model induced hallmark PCOS features including cystic ovarian lesions, a 75% increase in testosterone, insulin resistance, and ovarian fibrosis.

YOUR GUT IS MANAGING YOUR ESTROGEN

The estrobolome is the collection of gut bacteria responsible for metabolizing estrogen. These bacteria produce an enzyme called beta-glucuronidase, which reactivates conjugated estrogen metabolites in the intestine so they can be reabsorbed and recirculated. When the estrobolome is functioning correctly, your estrogen is balanced. When it is disrupted, you get either estrogen dominance — driving endometriosis, fibroids, and hormonal chaos — or estrogen deficiency, which drives anovulation, irregular cycles, and low follicular phase estrogen.

A 2025 systematic review of 12 studies confirmed that every major microplastic polymer type induces gut dysbiosis. The Firmicutes to Bacteroidetes ratio shifts. Anti-inflammatory genera that produce short-chain fatty acids decline. Intestinal permeability increases, flooding the bloodstream with LPS — bacterial endotoxin — which activates TLR4 and NF-kB and produces systemic inflammation that reaches the ovaries.

The gut-ovary axis is now a confirmed concept in reproductive science. Fecal transplant from women with ovarian disorders causes ovarian dysfunction in healthy mice. Fecal transplant from healthy donors restores estrous cycles in PCOS rats. In a 2025 mouse study, microplastic-induced follicle impairment occurred through this gut-ovary pathway, and fecal microbiota transplantation reversed it. The gut is not a peripheral system in the fertility investigation. It is running a central hormonal function, and what you eat — and what your food is wrapped in — is directly affecting it.

THE THYROID CASCADE NOBODY CONNECTS

Subclinical hypothyroidism is present in 14% of infertile women compared to just 4% of fertile women. This statistic is well-known in reproductive endocrinology. What is discussed far less is what is driving that number upward in the population, and whether plastic-associated chemical exposure is part of the answer.

The mechanism is layered. BPA and phthalates inhibit the deiodinase enzymes that convert inactive T4 into active T3. Phthalates raise thyroid-binding globulin, reducing the amount of free hormone available to your cells. PFAS competes directly with thyroid hormones for binding sites. A 2025 mouse study showed polystyrene microplastics directly downregulated TSH receptor gene expression in thyroid tissue.

The human data is already accumulating. A 2024 study of 287 subfertile women at a Massachusetts fertility clinic found that each quartile increase in total PFAS exposure corresponded to a 4.45% decrease in T3. Women with existing TPO antibody positivity saw TSH increase by 46 to 69% per interquartile range of PFAS — pushing borderline thyroid function firmly into subclinical hypothyroidism territory.

The ASRM confirmed in 2024 that TSH above 4.0 mIU/L is independently associated with increased miscarriage risk and that levothyroxine treatment improves outcomes in this population. The fertility cascade from thyroid dysfunction is direct: elevated TSH stimulates TRH, which raises prolactin, which suppresses GnRH pulsatility. Without adequate GnRH pulses, the LH surge is blunted or absent. Without the LH surge, ovulation does not occur on schedule.

Your TSH is on your fertility panel. The question of what is driving it upward belongs on that investigation too.

THE BRAIN, THE STRESS AXIS, AND YOUR PROGESTERONE

In 2024, researchers published in Nature Medicine that human brain tissue now contains up to 0.48% plastic by weight. Brains sampled in 2024 contained 50% more plastic than those from 2016. In individuals with dementia, concentrations were 10 times higher. In mouse studies, nanoplastics under 0.3 micrometers reach brain tissue within 2 hours of oral exposure, accumulating in microglia and triggering NF-kB-driven neuroinflammation. Dopamine production drops via tyrosine hydroxylase inhibition.

For fertility, the neuroendocrine consequence of this is the part that matters. Microplastics activate the HPA axis — your stress response system — raising cortisol 2 to 3 fold in animal models. BPA directly stimulates adrenal cortisol production. Sustained cortisol elevation reduces GnRH pulse frequency by 45 to 70%. The LH surge is delayed. Gonadotropin inhibitory hormone activates, shutting down the HPO axis from above.

The pregnenolone steal completes the picture. Under chronic HPA activation, the shared precursor pregnenolone is diverted toward cortisol synthesis at the expense of progesterone production. The result is functional progesterone deficiency without any structural diagnosis: shortened luteal phase, insufficient endometrial support for implantation, early pregnancy loss. Not because something is structurally wrong. Because your stress system is biologically robbing your reproductive system, driven in part by chemical exposure that is activating that stress response at the neuroendocrine level.

This is not “stress affects fertility” as a vague wellness concept. This is a documented mechanistic cascade.

THE COCKTAIL EFFECT — WHY THE SUM IS WORSE THAN THE PARTS

Standard toxicology tests one chemical at a time and establishes a threshold below which it is considered safe. That model was not built for the world you are actually living in.

You are exposed to dozens of plastic-associated chemicals simultaneously: BPA, phthalates, PFAS, flame retardants, UV stabilizers, plasticizers, and the environmental pollutants adsorbed onto microplastic surfaces before they reach your tissue. In a landmark 2007 analysis, Kortenkamp demonstrated that combinations of endocrine-disrupting chemicals produce significant biological effects even when every individual chemical is present below its established no-observed-adverse-effect level. He called it “something from nothing.” The individual doses are each technically safe. The combination is not.

Delfosse and colleagues confirmed in Nature Communications that two chemicals, each biologically inactive when tested alone, triggered substantial hormonal response when combined through synergistic co-binding in nuclear receptor ligand-binding pockets. The interaction created an effect that neither substance could produce on its own.

For reproductive health, this means that the absence of a single extreme exposure does not mean the absence of harm. The cumulative chemical burden across dozens of simultaneous low-level exposures is operating through pathways your current panels were not designed to detect.

WHAT YOU CAN ACTUALLY DO

You cannot achieve zero plastic exposure. What you can do is reduce the highest-impact routes — particularly during the preconception window and active IVF cycles, when your eggs are in their final 90-day maturation phase and most responsive to the cellular environment around them.

The single highest-impact change you can make is your water source. One liter of bottled water contains approximately 240,000 microplastic particles. Tap water filtered through reverse osmosis or activated carbon contains a fraction of that. Researchers estimate that people who drink exclusively bottled water ingest approximately 90,000 additional particles per year compared to filtered tap. This is the swap with the most evidence behind it, and it costs less than a month of bottled water.

Never heat food in plastic. Heat accelerates chemical leaching exponentially. BPA, phthalates, and other additives migrate into food far faster under thermal stress than at room temperature. Glass, stainless steel, and ceramic for all hot food storage and preparation. Do not microwave plastic containers. Do not run them through the dishwasher. Retire scratched plastic immediately — damage to the surface dramatically increases leaching.

Canned food is a consistent and underappreciated source. Most can linings use bisphenol alternatives with similar receptor-binding profiles to BPA. Fresh or frozen food in glass is always preferable. The BPA-free label on a can does not mean safe. Look for products that specify no bisphenols — not just no BPA.

Indoor air is a significant source that most people are not thinking about, primarily from synthetic textile dust. HEPA air filtration at home reduces inhaled microplastic load. Given how many hours are spent indoors, this is not a minor exposure.

From a supplementation standpoint, oxidative stress is the single most consistently replicated mechanism of microplastic harm in reproductive tissue. NAC has rescued microplastic-induced ovarian dysfunction in rat studies. Melatonin — which functions as a key antioxidant in follicular fluid and is disrupted by circadian disruption and sleep loss — has been shown to improve fertilization rates in IVF patients with prior low fertilization. These are not unfounded recommendations, but specific supplementation should be discussed with your care team based on your individual picture.

The most important thing, though, is not any single swap. It is understanding that microplastics operate through at least six distinct biological pathways — and that reducing one input while the others remain unaddressed is incomplete investigation. If your thyroid, gut microbiome, immune markers, cortisol dynamics, and environmental exposures have never been assessed as part of your fertility workup, the investigation is not finished.

THE INVESTIGATION STARTS WITH A QUESTION

This is what OVAHaul was built to do — to ask the questions that the standard fertility workup is not structured to ask. Not to replace your reproductive endocrinologist or your embryologist. To go deeper into the systems that surround the egg, the uterus, and the embryo and find what has been overlooked.

If any part of what you read in this issue connects to something you have been experiencing — the unexplained results, the cycle that should have worked, the labs that all came back normal while something clearly is not right — there is a place to start.

The Fertility Disruptors Quiz is 30 questions. It covers hormone balance, metabolic health, immune function, thyroid dynamics, stress and nervous system function, gut health, nutritional status, and environmental exposures. At the end, you receive a personalized report identifying the areas of your biology that most warrant investigation, based on the same 10-systems framework I use in clinical practice.

It takes about 10 minutes. It might reframe the last few years.

Take the Fertility Disruptors Quiz here: TAKE THE QUIZ

If you’re interested in chatting more about your journey and what next steps to take in your investigation, I have free logistics calls to help you decide the best next steps.
BOOK YOUR CALL HERE.

The investigation is not over.

With you every step of the way,

Lindsay Chu
Founder of OVAHaul
Clinical Embryologist

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

A NOTE ON THE RESEARCH

I want to be transparent about what this evidence does and does not establish. Human studies confirming microplastics in follicular fluid and reproductive tissue are recent, and sample sizes are still small (n=18 to 45 in the key studies). Correlations with fertility markers exist, but prospective cohort studies establishing causal proof in humans do not yet exist. The field is that new. The mechanistic data from animal and in vitro models is robust and consistent across species, and the pathways of harm are well-characterized. But I am not telling you that microplastics are definitively causing your infertility. I am telling you that they are confirmed inside the tissue where fertility happens, that the biological mechanisms match what we know about egg quality and implantation, and that the precautionary case for reducing exposure — especially during a preconception or IVF window — is strong.

The investigation is not over. That is not fear. That is science.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

KEY SOURCES

• Montano M et al. First evidence of microplastics in human ovarian follicular fluid. Ecotoxicol Environ Saf. 2025. Yan S et al. Polyethylene microplastic exposure adversely affects oocyte quality in human and mouse.

• Environ Int. 2024. Zhejiang University. Associations between microplastics in follicular fluid and the risk of diminished ovarian reserve.

• J Hazard Mater. 2025. Sun X et al. Detection and quantification of microplastics in human endometrium.

• Sci Total Environ. 2024. Qin et al. Features, potential invasion pathways, and reproductive health risks of microplastics detected in human uterus.

• Environ Sci Technol. 2024. An Q et al. Polystyrene microplastics cause granulosa cell apoptosis and fibrosis in ovary through oxidative stress.

• Toxicology. 2021. Xue Z et al. Polystyrene nanoplastics induce apoptosis, autophagy, and steroidogenesis disruption in granulosa cells via PI3K/AKT.

• J Nanobiotechnol. 2024. Campen M et al. Microplastics in human brain tissue. Nature Medicine. 2024. Derakhshan A et al. PFAS and thyroid hormone disruption in subfertile women at a fertility clinic.

• Environ Health Perspect. 2024. Ervin SM et al. Gut microbial beta-glucuronidases reactivate estrogens as components of the estrobolome.

• J Biol Chem. 2019. Kortenkamp A. Ten years of mixing cocktails: a review of combination effects of endocrine-disrupting chemicals.

• Environ Health Perspect. 2007. Cox K et al. Human consumption of microplastics.

• Environ Sci Technol. 2019. Vandenberg LN et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses.

• Endocr Rev. 2012. ASRM Practice Committee. Subclinical hypothyroidism in the infertile female population: a guideline. 2024.

If you have been trying to conceive and something is not working, you have probably had bloodwork done. Maybe more than once. And maybe you have been told everything looks normal.

I want to talk about what that actually means. Because “normal” in a standard fertility panel means you have not crossed a diagnostic threshold. It does not mean every system involved in getting and staying pregnant has been looked at. It does not mean the investigation is complete. It just means the basic screen did not flag anything obvious.

That is not nothing. But it is also not enough.

Your fertility is not controlled by one hormone or one marker. It is the output of ten biological systems working together. Your hormones, your immune system, your metabolism, your mitochondria, your thyroid, your clotting system, your methylation pathways, your gut, your nutrient status, and your stress response. When a cycle fails or a pregnancy does not hold, the answer is almost never in the one marker your doctor checked. It is usually sitting in a system that was never investigated at all.

That is what OVAHaul bloodwork is built to find.

Below I am walking you through all ten systems. What we measure, what symptoms point there, and what we actually do with the information. My hope is that by the end of this, you understand your own biology a little better regardless of what you decide to do next.

And if you want to know which systems are most likely disrupted for you specifically, take the free OVAHaul Fertility Systems Assessment first. It takes a few minutes and it will show you exactly where to focus.

Take the Free Assessment

System 1: Hormonal

What we measure: Estradiol, FSH, LH, total and free testosterone, progesterone, SHBG, AMH, prolactin, DHEA-S.

Symptoms that point here: Irregular or absent periods. Cycles shorter than 24 or longer than 35 days. Poor stimulation response in IVF. Symptoms of androgen excess like acne, hair thinning, or excess facial hair. Low libido. Signs of low progesterone in the second half of your cycle.

What we do with it: We read these markers as a pattern, not in isolation. An FSH of 8 means something different when estradiol is suppressed on cycle day 3. Free testosterone is the biologically active form and changes how we interpret androgen-related symptoms. SHBG tells us how much is actually available to your tissues. The pattern guides stimulation protocol decisions, supplement support, and whether deeper investigation into androgens or adrenal function is warranted.

System 2: Immune and Autoimmune

What we measure: ANA with titer and pattern, antiphospholipid antibodies, lupus anticoagulant, antiphosphatidylserine antibodies, D-dimer, fibrinogen, anti-dsDNA, Sjogrens antibodies, rheumatoid factor, complement C3 and C4, celiac screening.

Symptoms that point here: Recurrent implantation failure. Recurrent early pregnancy loss. Chemical pregnancies. A history of autoimmune conditions in you or a first-degree relative. Unexplained fatigue, joint pain, or skin changes. IVF cycles that fail despite good embryo quality.

What we do with it: A positive ANA with a specific pattern opens the full immune investigation. Antiphospholipid findings are actionable, low-dose aspirin and anticoagulation protocols exist and work. Silent celiac is modifiable through diet. Identifying active immune dysregulation through complement levels tells us whether the implantation environment is being disrupted right now.

System 3: Metabolic and Insulin Signaling

What we measure: Fasting insulin, fasting glucose, HOMA-IR, hemoglobin A1c, comprehensive metabolic panel, lipid panel with ratios, uric acid, leptin, adiponectin, IGF-1.

Symptoms that point here: Irregular cycles. PCOS diagnosis or suspicion. Difficulty losing weight or unexplained weight gain. Sugar cravings or energy crashes after meals. Skin tags. Darkening skin in skin folds. History of gestational diabetes. Poor embryo quality despite good stimulation.

What we do with it: HOMA-IR is the calculated marker most people have never had. It catches insulin resistance before blood sugar moves. Findings here directly inform nutritional strategy, inositol dosing, medication consideration, and stimulation protocol adjustments. Adiponectin gives us the earliest signal of metabolic dysfunction. IGF-1 tells us how sensitively your ovaries will respond to stimulation, which matters for both poor responders and PCOS patients at risk of overstimulation.

System 4: Mitochondrial and Oxidative Stress

What we measure: CoQ10, GGT, free and total carnitine, thiamine, RBC magnesium, selenium, zinc.

Symptoms that point here: Poor embryo quality or development in IVF. High fragmentation. Embryo arrest. Repeated euploid embryo transfer failures. Unexplained egg quality concerns. Fatigue that is disproportionate to your lifestyle.

What we do with it: These are not supplement guesses. They are measurements. Low CoQ10 informs targeted dosing of ubiquinol at a therapeutic level, not a generic wellness dose. Carnitine deficiency changes the fuel available inside your eggs at the moment of fertilization and early division. GGT reflects glutathione status, your master antioxidant. We supplement to the gap, not to the assumption.

System 5: Coagulation and Thrombophilia

What we measure: Factor V Leiden, Prothrombin Factor II G20210A, PAI-1 4G/5G genotype, Lp(a), Protein C, Protein S, Antithrombin III activity.

Symptoms that point here: Recurrent pregnancy loss. Recurrent IVF failure with good quality embryos. Chemical pregnancies. Personal or family history of blood clots, DVT, or stroke. Placental complications in a prior pregnancy. Unexplained implantation failure.

What we do with it: Genetic thrombophilias are run once per lifetime. Functional protein levels tell us what is happening right now. Findings here directly inform decisions around low-dose aspirin, anticoagulation therapy, and how frozen embryo transfer cycles are managed. These findings are treatable. That is the entire point of finding them.

System 6: Chromosomal and Genetic

What we measure: Homocysteine, RBC folate, vitamin B12, MTHFR C677T and A1298C genotype, methylmalonic acid, vitamin B6, serum folate.

Symptoms that point here: High rates of chromosomally abnormal embryos in IVF. Recurrent pregnancy loss. Neural tube defect history. Known MTHFR variant without proper follow-up. Elevated homocysteine on prior labs. Poor response to standard folic acid supplementation.

What we do with it: MTHFR does not doom you. It changes your protocol. Specifically, whether you need methylated B vitamins rather than standard folic acid, and at what dose. Methylmalonic acid tells us whether your B12 is actually functional at the tissue level, not just present in your blood. Elevated homocysteine is addressable through targeted B vitamin support once we know which pathway is the bottleneck.

System 7: Gut Health and Microbiome

What we measure: tTG-IgA and total IgA for celiac screening, immunoglobulin panel for absorption context, iodine through spot urine, indirect markers of gut function through nutrient status across the full panel.

Symptoms that point here: Bloating, irregular bowel habits, or digestive discomfort. Nutrient deficiencies that persist despite supplementation. Autoimmune history. Thyroid dysfunction. Recurrent pregnancy loss with no clear cause. Following a gluten-free, dairy-free, or heavily restricted diet.

What we do with it: Silent celiac is one of the most modifiable causes of recurrent loss and nutrient malabsorption in reproductive-age women. It does not always look like a gut problem. If celiac screening is positive, dietary modification is the intervention and it is meaningful. Persistent nutrient deficiencies despite supplementation redirect us to absorption as the issue, not intake.

System 8: Thyroid

What we measure: TSH, free T3, free T4, TPO antibodies, thyroglobulin antibodies, reverse T3, ACTH, Free T3 to Reverse T3 ratio.

Symptoms that point here: Irregular cycles. Recurrent miscarriage. Cold intolerance. Fatigue. Hair loss. Constipation. Brain fog. TSH that has been flagged as borderline. Known Hashimotos or family history of thyroid disease. Poor IVF response. Luteal phase dysfunction.

What we do with it: We interpret against fertility-optimized ranges. TSH above 2.5 is associated with higher miscarriage rates in cohorts I find compelling. The standard range allows up to 4.5 or higher. That gap matters. A positive antibody result with normal TSH still changes the clinical picture. Reverse T3 elevation tells us whether chronic stress is creating a functional thyroid slowdown that standard panels will miss entirely.

System 9: Nutritional and Nutrigenomic

What we measure: Vitamin D, iron, TIBC, ferritin, RBC magnesium, zinc, selenium, vitamin A, vitamin E, omega-3 index, copper, iodine, RBC folate, B12, homocysteine.

Symptoms that point here: Fatigue. Poor egg quality. Thin uterine lining. Recurrent loss. Known deficiencies that have not been properly addressed. Taking multiple supplements without ever confirming whether they are working. Restricted dietary patterns.

What we do with it: We assess against fertility-optimized ranges, not general population reference ranges. Ferritin is the most sensitive early marker of iron deficiency and we look at it before anemia develops. Vitamin D is interpreted with a higher target in mind because the reproductive literature supports it. We supplement to the specific gap identified, not to a generic prenatal protocol. If you have been told your levels are fine and something still feels off, the range being used to define fine matters.

System 10: Nervous System and Stress

What we measure: Morning serum cortisol, ACTH, reverse T3, Free T3 to Reverse T3 ratio.

Symptoms that point here: Cycle irregularity that worsens during high-stress periods. Poor sleep. Anxiety. Fatigue that is not explained by thyroid or iron. History of hypothalamic amenorrhea. Feeling wired and tired simultaneously. IVF cycles that seem to underperform relative to your reserve and protocol.

What we do with it: Chronic cortisol elevation directly suppresses GnRH, the hormone that initiates the entire reproductive cascade. Less GnRH means less FSH and LH. That is not a metaphor. That is documented physiology. Elevated cortisol with a low Free T3 to Reverse T3 ratio tells us your body is in conservation mode and your reproductive system is paying the price. Findings here redirect us toward nervous system support as a genuine clinical priority, not a wellness afterthought.

Ten systems. Mapped. Measured. Interpreted through a reproductive lens.

If you are not sure where your investigation should start, the assessment will point you in the right direction.

Take the free OVAHaul Fertility Disruptors Assessment

Ready to go deeper? The OVAHaul bloodwork is available now for US-based patients. Cycle day 3 draw.

The investigation is not over until we have looked everywhere it could possibly be.

OVAHaul Fertility Systems Bloodwork HERE

Here’s a video to walk you through set up:

How to Sign Up for OVAHaul Blood Work and Understand Your Results 🩸 - Watch Video

With you every step,
Lindsay Chu
Founder of OVAHaul
Clinical Embryologist

PS. If you’re looking to take the bloodwork to your physician to get it covered under insurance, you can find the entire list here: Full List of Blood Panels

Picture your ovaries not as quiet storage rooms for eggs, but as living, pulsing neighborhoods. Tiny blood vessels bring in oxygen and nutrients. Immune cells patrol like security. Fibroblasts lay down scaffolding and, with age, sometimes too much scar. And weaving through all of it, like fiber-optic cables in a busy city, are nerves.

Not just any nerves. The same “fight-or-flight” sympathetic nerves that fire when your heart races, your palms sweat, and your mind spins at 2am. Those nerves do not just live in your chest or your brain. They thread directly into your ovaries, wrapping around the follicles that will one day become your eggs.

In 2025, a team at UCSF did not just suspect this, they saw it.

The study that turned the ovary into an ecosystem

Using a new 3D imaging technique, scientists at UCSF took whole ovaries, not thin slices on a slide but intact organs, and made them optically clear. Then they lit them up. Under the microscope, the ovary transformed into a glowing map of cells, vessels, and nerves.

They also sequenced nearly 100,000 individual ovarian cells from mice and humans, including eggs hand isolated one by one because of how large and fragile they are. The result was the most detailed atlas of the ovary ever created, not just what cells are there, but how they are wired together and how that wiring changes with age.

Here is what they found, in plain language

Sympathetic “fight-or-flight” nerves form dense networks throughout the ovary. The same nerves that surge when you are stuck in traffic, doomscrolling, or waiting for lab results are physically embedded in the tissue that grows your eggs.

Those nerves get thicker and more abundant with age. A 55 year old ovary looks more wired than a 23 year old one, like someone kept adding more and more cables over the years.

When these nerves are cut or silenced in animal models, more follicles stay asleep in reserve and fewer make it to maturity. The nervous system is literally part of the decision about which eggs wake up and start growing.

For the first time, brain like glial cells were found in the ovary, sitting alongside those nerves. Your ovary does not just have wiring, it has local neural support staff.

Eggs do not float alone. They sit in little pockets surrounded by fibroblasts, blood vessels, connective tissue, and nerves, an ecosystem that frays, scars, and inflames decades earlier than in organs like the lung or liver.

When the lead scientist says ovarian aging is about the egg’s ecosystem, not just the egg, this is what she means. Your ovary is not an egg warehouse. It is a neuro immune vascular organ.

And if that is where your eggs live, then anything that changes that ecosystem, including stress, has a direct line to your fertility.

Stress is not just in your head. It is in your ovaries.

For more than 40 years, researchers have been quietly documenting something medicine has been slow to fully integrate. The sympathetic nervous system does not just make you feel stressed. It talks directly to your ovaries.

Nerves carrying norepinephrine reach the ovary along defined pathways from your spinal cord. The majority of the norepinephrine inside the ovary comes from these nerve endings. They help decide how much blood flows through the ovary, how responsive granulosa cells are to FSH, and which follicles stay in reserve versus which are recruited.

In animal studies, when scientists surgically cut or chemically silence these sympathetic nerves, follicles stall, estradiol drops, ovulation can be delayed, and cystic changes shift. In PCOS models, sympathetic overactivation shows up before the ovaries become polycystic. Norepinephrine rises first, cysts follow later. In some experiments, simply exposing animals to cold stress for a few hours a day was enough to push their ovaries toward a PCOS like state.

In other words, chronic sympathetic activation leaves a fingerprint on the ovary. It is not just a feeling. It is a physical imprint.

Human data echo this at the clinical level

Women who report higher perceived stress tend to have lower AMH and fewer antral follicles, with the strongest effects in younger women.

Markers of sympathetic activation in saliva, such as alpha amylase, correlate with lower AMH and lower chances of getting pregnant more strongly than cortisol does in some cohorts.

In IVF cycles, higher stress hormones inside the follicular fluid are associated with poorer embryo quality and lower pregnancy rates.

Psychological stress can shift the gene expression landscape of the endometrium and is linked to higher chances of non pregnancy and early loss.

Interventions that actively shift autonomic tone, such as mind body programs and CBT based approaches, have improved pregnancy rates in randomized trials.

So when we say “stress talks to your eggs,” this is what we are pointing to. A racing mind connects to firing nerves, which drive norepinephrine release, which tunes the microenvironment bathing your ovarian follicles and your endometrium.

Why OVAHaul has always treated your body as an ecosystem

Before this study, OVAHaul built its framework around 10 interconnected systems that shape the world your eggs live in. Hormonal. Immune and autoimmune. Metabolic and insulin signaling. Mitochondrial and oxidative stress. Coagulation and thrombophilia. Chromosomal and genetic. Gut and microbiome. Thyroid. Nutritional and nutrigenomic. And nervous system and stress.

This new ovarian atlas does not just support that idea. It crystallizes it.

If your ovaries are wired by stress responsive nerves, supported by immune and fibroblast cells that can inflame and scar early, dependent on mitochondria in granulosa cells to generate the ATP your eggs need, and sensitive to insulin and metabolic signals that alter sympathetic tone, then looking only at AMH, FSH, ultrasound images, and semen parameters will always be incomplete.

Standard fertility care often starts with questions like “What are your numbers, what is your diagnosis, what treatment do we move to next”

OVAHaul starts somewhere else. “What is the state of the ecosystem around your eggs”

Because in the 2 to 3 months before an egg retrieval, the time when follicles are being recruited, growing, and maturing, your nervous system, metabolism, mitochondria, immune system, and hormones all share that space.

A person with insulin resistance is more likely to have elevated sympathetic tone. Someone with chronic gut inflammation may have disrupted vagal signaling. Someone with a trauma history may live in a body that rarely feels fully off duty. Someone with mitochondrial strain may have granulosa cells that cannot keep up when sympathetic firing raises the energy demand.

The UCSF findings stitch these realities together at the anatomical level. The nerves are there. The ecosystem matters. And it ages with you.

If you are preparing for IVF, this is your window

If sympathetic nerves help decide which eggs wake up from dormancy and how follicles progress, then the weeks leading into an IVF stimulation are not neutral. They are the window where your nervous system, along with the other nine systems, is literally helping curate the cohort of eggs you will retrieve.

Within OVAHaul’s lens, “stress management” is not a side note or an inspirational quote at the bottom of your lab report. It looks like

Assessing how your autonomic nervous system behaves over time, for example through heart rate variability, sleep patterns, and symptom patterns.

Surfacing the long term loads your body has been carrying, trauma, burnout, chronic sleep debt, caregiving strain, financial pressure.

Identifying biological amplifiers, insulin resistance, inflammation, thyroid issues, mitochondrial strain, micronutrient gaps.

Implementing nervous system aware strategies that aim to shift your baseline, not just soothe you for ten minutes, such as structured mind body interventions, trauma informed approaches, HRV biofeedback, and where appropriate, modalities like electroacupuncture.

Once you see your ovary as a lit up, innervated ecosystem, it becomes much harder to believe that stress is “soft,” immeasurable, or irrelevant. The relationship between stress and fertility is not just emotional. It is anatomical. It is measurable. And it is modifiable.

A note if you are on the OVAHaul Blood Testing waitlist

If you joined the OVAHaul Blood Testing email waitlist, this is the moment we have been getting ready for together. Starting today, you will receive a guided email series that walks you system by system through the 10 fertility domains our bloodwork panels are built to investigate.

In your inbox, you will see how we go beyond AMH to map the nervous system and stress signatures in your labs, the immune and inflammatory patterns that shape ovarian scarring and implantation, and the metabolic and insulin signals that intersect with PCOS and egg development. You will also see how we look at mitochondrial and oxidative stress markers that reflect the energy capacity of your granulosa cells, along with thyroid, coagulation, gut and microbiome, genetic, and micronutrient panels that fill in the rest of your fertility ecosystem.

You will also be receiving a sneak peak of the panels, discounts on OVAHaul Programs, and the ability to sign up before the bloodwork panel is shared to this newsletter list and our socials accounts.

If you signed up and do not see anything yet, check your promotions and spam folders, then mark OVAHaul as safe so you do not miss the rest of the series. When your first email lands, set aside a few quiet minutes to read it, because it is your starting point for turning abstract symptoms into concrete, testable data you can act on.

If you could change one thing about how your body feels going into IVF, whether it is sleep, anxiety, energy, or specific symptoms, what would you choose to start with?

With you every step of the way,

Lindsay Chu
Founder of OVAHaul

Sources

• Gaylord EA et al. Comparative analysis of human and mouse ovaries across age. Science. 2025.

• Laird DJ lab and Chan Zuckerberg Biohub San Francisco, related preprint and institutional communications.

• Peer reviewed research on sympathetic innervation of the ovary, norepinephrine signaling, PCOS models, and ovarian aging.

• Mínguez Alarcón L et al. Perceived stress and markers of ovarian reserve among subfertile women. Reproductive Biomedicine Online. 2023.

• Studies on environmental and psychological stressors, AMH, and autonomic markers such as salivary alpha amylase.

• Clinical and mechanistic studies on stress hormones, endometrial gene expression, IVF outcomes, and mind body interventions in fertility.

Earlier today I shared the 10 fertility systems that standard workups miss.

Now I want to tell you what is coming next.

OVAHaul testing is launching soon. And the people on the waitlist are getting first access when we go live.

But there is one more thing I have not announced publicly yet.

When you join the bloodwork waitlist, you will receive an exclusive discount on the Deep Dive Analysis and Protocol.

Instead of second-guessing your next step or scrolling through Instagram trying to piece together what might help, you will have a clear, personalized plan based on your actual data. The goal is simple: identify what is truly influencing your fertility and focus on the factors that can move the needle in your journey.

The Deep Dive is where your bloodwork stops being a list of numbers and becomes a map. Every marker in clinical context. Every system investigated. A real picture of what is actually happening, and what is worth addressing before your next cycle.

Starting Monday, March 9th, waitlist members start receiving all the details first. How the testing works. What the panels include. How to get started.

If you read this morning’s newsletter and something clicked, this is the next step.

Join the OVAHaul Testing Waitlist →

Spots are limited and Monday is close.

With you every step,
Lindsay Chu
Founder of OVAHaul

www.ovahaul.com